Found 582 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Randomized Double-Blind Placebo-Controlled Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B …
A Phase 2 Randomized Open-Label Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV
This is a Phase 2, randomized, open-label, active-controlled, multicenter study to evaluate the safety, efficacy, and PK of ISL + LEN. The target population is virologically suppressed people living with HIV (PWH) who are at least 18 years of age and meet other study inclusion criteria. All participants will be …
Polysomnography Validation of the Sansa Device
The purpose is to validate the Huxley Sansa device and automated scoring algorithm for detecting SDB events compared to the reference standard in-lab PSG. Participants will be recruited from Penn patients age 18+. This is a multi-site, sponsored study where Penn will rely on a central IRB, with enrollment across …
AIR-B4: Mind the Gap (MTG)
The AIRB research team will compare the use and effectiveness of each intervention (Mind the Gap, Remaking Recess and Self Determination Learning Model of Instruction) with and without the addition of an implementation strategy, UNITED. In all groups, the research team will train community practitioners using remote delivery of professional …
A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation
In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of paroxysmal or persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will randomize in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, preferably administered …
PTSD Treatment Study
Have you experienced a traumatic event that affected your life significantly? You may be eligible to participate in a study conducted by the Center for the Treatment and Study of Anxiety at the University of Pennsylvania.In this study we will investigate the influence of gonadal hormones on fear acquisition and extinction …
Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's …
A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy
A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, …
Post Approval Study of the remed System
This Post Approval Study is a multi-center, prospective, open label, single arm cohort study to evaluate the long-term safety, long-term effectiveness, and survival rate in subjects implanted with the remed System from the remed System Pivotal Trial. Up to 94 subjects will be enrolled at up to 21 sites in …
A Phase 1/2 Study of Oral LOXO-292 in Patients
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
Please choose between Voice or SMS based delivery of verification code
or